James F. Casella, MD; Bruce A. Barton, PhD; Julie Kanter, MD; et al.
doi : 10.1001/jama.2021.3414
JAMA. 2021;325(15):1513-1523.
This phase 3 trial examines the effectiveness of poloxamer 188 in reducing the duration of painful vaso-occlusive episodes in children and adults with sickle cell disease compared with placebo.
The Writing Committee for the COMEBAC Study Group
doi : 10.1001/jama.2021.3331
JAMA. 2021;325(15):1525-1534.
This French cohort study describes coronavirus disease sequelae at 4 months in patients hospitalized for COVID-19 between March and May 2020, including assessment of respiratory, cognitive, and functional symptoms and test and imaging findings.
Kathryn E. Stephenson, MD, MPH; Mathieu Le Gars, PhD; Jerald Sadoff, MD; et al.
doi : 10.1001/jama.2021.3645
JAMA. 2021;325(15):1535-1544.
This randomized trial compares the immunogenicity of a SARS-CoV-2 Ad26.COV2.S vaccine at high vs low vs no dose (placebo) in humans, including the kinetics, magnitude, and phenotype of coronavirus spike-specific humoral and cellular immune responses.
Eric J. Nelson, MD, PhD, MS; Sarah L. McKune, PhD, MPH; Kathleen A. Ryan, MD; et al.
doi : 10.1001/jama.2021.2392
JAMA. 2021;325(15):1561-1562.
This study describes coronavirus test positivity rates among elementary, middle, and high school student contacts of confirmed COVID-19 cases in a Florida county where schools required a negative test on day 9 before return to school on day 10.
Kimberly G. Blumenthal, MD, MSc; Lacey B. Robinson, MD, MPH; Carlos A. Camargo Jr, MD, DrPH; et al.
doi : 10.1001/jama.2021.3976
JAMA. 2021;325(15):1562-1565.
This study examines the incidence of acute allergic reactions to mRNA COVID-19 vaccine administrations in health care employees in Massachusetts.
Athalia Christie, MIA; Sarah A. Mbaeyi, MD; Rochelle P. Walensky, MD
doi : 10.1001/jama.2021.4367
JAMA. 2021;325(15):1501-1502.
This Viewpoint summarizes CDC activity recommendations for individuals fully vaccinated against SARS-CoV-2 infection, including resumption of low-risk gatherings among vaccinated people and maintenance of public health measures in activities involving unvaccinated people.
Rachel Wilf-Miron, MD, MPH; Vicki Myers, PhD; Mor Saban, PhD
doi : 10.1001/jama.2021.4300
JAMA. 2021;325(15):1503-1504.
This Viewpoint explains the “green pass” program in Israel to encourage residents to seek COVID-19 vaccination, with incentives including access to social, cultural, and sports events and gyms, hotels, and restaurants as well as exemption from quarantine after travel or exposure to an individual with SARS-CoV-2 infection.
Kimberly Maxfield, PhD; Issam Zineh, PharmD, MPH
doi : 10.1001/jama.2021.1004
JAMA. 2021;325(15):1505-1506.
This Viewpoint describes the concept of precision drug dosing, which would maximize drug benefit and minimize harm for each patient, and reviews the scientific, regulatory, technical, and practical infrastructures that would need to be in place for the idea to become reality in clinical practice settings.
Edward H. Shortliffe, MD, PhD; Gary H. Lyman, MD, MPH; Francis K. Amankwah, MPH
doi : 10.1001/jama.2021.2414
JAMA. 2021;325(15):1507-1508.
This Viewpoint summarizes a 2021 NASEM report that makes policy recommendations to reduce systems inefficiencies that lead to discarded medications in the US, including development of standards to allow safe use of single-dose vials across multiple patients, and use of payment models to reimburse treatment episodes rather than drug vial volume or cost.
Alexander Zider, MD
doi : 10.1001/jama.2021.4885
JAMA. 2021;325(15):1509-1510.
In this narrative medicine essay, a pulmonologist learns about process improvement from his father, an engineer, who drew up a list of 50 improvements he noted during his hospitalizations for prostate cancer.
Hallie C. Prescott, MD, MSc
doi : 10.1001/jama.2021.3430
JAMA. 2021;325(15):1511-1512.
Hassan Kamran, MD; Hani Jneid, MD; Waleed T. Kayani, MD; et al.
doi : 10.1001/jama.2021.0716
JAMA. 2021;325(15):1545-1555.
This narrative review summarizes oral antiplatelet therapy and specifically addresses the effects of dual antiplatelet therapy for patients with acute coronary syndrome who have not taken anticoagulants.
Rajeev Anchan, MD; Adam S. Cifu, MD; Jonathan Paul, MD
doi : 10.1001/jama.2021.2744
JAMA. 2021;325(15):1556-1557.
This JAMA Clinical Guidelines Synopsis summarizes the European Society of Cardiology’s 2020 recommendations for management of patients with non–ST-segment elevation acute coronary syndromes.
Shana E. Gleeson, MD; Xuchen Zhang, MD, PhD; Marwan M. Azar, MD
doi : 10.1001/jama.2021.0368
JAMA. 2021;325(15):1558-1559.
A 28-year-old man who while traveling swam in the upper Nile River in Uganda developed intermittent diarrhea and hematochezia but no vomiting, fever, or weight loss; physical examination and laboratory findings were unremarkable, and colonoscopy with biopsy showed rectal granulomas containing oval-shaped features with lateral spines. What is the diagnosis and what would you do next?
Jody Zylke, MD
doi : 10.1001/jama.2021.3399
JAMA. 2021;325(15):1524.
Mary Chris Jaklevic, MSJ
doi : 10.1001/jama.2021.2018
JAMA. 2021;325(15):1492-1493.
This Medical News article describes a call for guidelines to establish a standard time interval for follow-up colonoscopy after an abnormal fecal test result for colon cancer screening.
Mary Chris Jaklevic, MSJ
doi : 10.1001/jama.2021.3165
JAMA. 2021;325(15):1494-1495.
This Medical News article describes a trial of intensive behavioral interventions at primary-care clinics for low-income patients with obesity.
Mary Chris Jaklevic, MSJ
doi : 10.1001/jama.2021.5391
JAMA. 2021;325(15):1499.
Mary Chris Jaklevic, MS
doi : 10.1001/jama.2021.5121
JAMA. 2021;325(15):1499.
Mary Chris Jaklevic, MSJ
doi : 10.1001/jama.2021.5393
JAMA. 2021;325(15):1499.
Sherry Glied, PhD
doi : 10.1001/jama.2021.4640
JAMA. 2021;325(15):1496-1497.
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2021.4494
JAMA. 2021;325(15):1498.
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2021.5498
JAMA. 2021;325(15):1498.
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2021.5500
JAMA. 2021;325(15):1498.
Angel N. Desai, MD, MPH; Rocio Hurtado, MD, DTM&H
doi : 10.1001/jama.2020.19062
JAMA. 2021;325(15):1574.
This JAMA Patient Page describes the risk factors, symptoms, diagnosis, treatment, and prevention measures for nontuberculous mycobacterial infections.
Edward H. Livingston, MD; Preeti N. Malani, MD, MSJ; C. Buddy Creech, MD, MPH
doi : 10.1001/jama.2021.2927
JAMA. 2021;325(15):1575.
This JAMA Patient Page explains how the Johnson & Johnson COVID-19 vaccine, likely to be the third SARS-CoV-2 vaccine approved for widespread use, uses an adenovirus 26 vector to deliver coronavirus DNA to host cells to produce spike proteins and safely and effectively induce immunity.
Gianluca Rigatelli, MD, PhD; Marco Zuin, MS
doi : 10.1001/jama.2021.1435
JAMA. 2021;325(15):1565.
Maneesh Sud, MD; Jiming Fang, PhD; Dennis T. Ko, MD, MSc
doi : 10.1001/jama.2021.1441
JAMA. 2021;325(15):1565-1566.
Zachary R. McCaw, PhD; Lu Tian, ScD; Lee-Jen Wei, PhD
doi : 10.1001/jama.2021.1700
JAMA. 2021;325(15):1566-1567.
Ary Serpa Neto, MD, MSc, PhD; Anna Geke Algera, MD; Marcus J. Schultz, MD, PhD; et al.
doi : 10.1001/jama.2021.1703
JAMA. 2021;325(15):1567-1568.
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟